Design Therapeutics, Inc. DSGN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.77M-6.6% | $16.86M-25.3% | $15.09M-50.3% | $19.7M-56.9% | $13.67M-53.5% | ||
| $210.05M-2.8% | $202.99M-8.9% | $190.88M-14.7% | $196.57M-8.7% | $216.01M-10.5% | ||
| $14.74M+9.0% | $14.49M+13.6% | $13.11M+1.0% | $13.22M-1.5% | $13.53M+7.8% | ||
| $227.05M-2.8% | $223.78M-9.8% | $209.03M-18.7% | $219.79M-17.0% | $233.64M-14.7% | ||
| $824K-40.2% | $981K-30.4% | $1.1M-29.2% | $1.26M-27.2% | $1.38M-19.8% | ||
| $2.57M+26.7% | $1.44M-35.1% | $1.64M-31.8% | $1.83M-29.0% | $2.03M-26.6% | ||
| —— | $0-100% | $0-100% | $0-100% | $427K0.0% | ||
| $230.44M-3.0% | $226.2M-10.3% | $211.77M-19.1% | $222.89M-17.3% | $237.48M-14.8% | ||
| $2.28M-28.4% | $2.31M+5.8% | $1.91M+30.1% | $1.01M-21.9% | $3.18M+132% | ||
| $536K-34.7% | $890K+11.3% | $866K+11.3% | $844K+11.5% | $821K+11.5% | ||
| $10.19M+23.7% | $13.06M+54.3% | $11.17M+50.3% | $8.75M+36.8% | $8.24M+16.1% | ||
| $2.2M+66.5% | $645K-58.0% | $877K-49.7% | $1.1M-43.4% | $1.32M-38.4% | ||
| $2.73M+27.7% | $1.54M-34.2% | $1.74M-30.9% | $1.95M-28.0% | $2.14M-25.6% | ||
| $12.39M+29.6% | $13.7M+37.1% | $12.05M+31.3% | $9.85M+18.1% | $9.56M+3.5% | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $532.96M+12.8% | $509.1M+8.6% | $480.37M+3.3% | $476.74M+3.2% | $472.39M+3.0% | ||
| -$314.64M-28.5% | -$297.01M-30.7% | -$281.01M-31.6% | -$264.01M-31.7% | -$244.93M-29.8% | ||
| -$268K-160% | $403K-15.2% | $358K-60.8% | $305K+241% | $450K+369% | ||
| $218.05M-4.3% | $212.5M-12.2% | $199.72M-20.9% | $213.04M-18.5% | $227.92M-15.4% | ||
| $230.44M-3.0% | $226.2M-10.3% | $211.77M-19.1% | $222.89M-17.3% | $237.48M-14.8% | ||
| $210.05M-2.8% | $202.99M-8.9% | $190.88M-14.7% | $196.57M-8.7% | $216.01M-10.5% | ||
| $2.57M+26.7% | $1.44M-35.1% | $1.64M-31.8% | $1.83M-29.0% | $2.03M-26.6% | ||
| $2.57M+26.7% | $1.44M-35.1% | $1.64M-31.8% | $1.83M-29.0% | $2.03M-26.6% | ||
| $2.57M+26.7% | $1.44M-35.1% | $1.64M-31.8% | $1.83M-29.0% | $2.03M-26.6% | ||
| $7.91M+56.5% | $10.74M+71.2% | $9.26M+55.3% | $7.73M+51.7% | $5.06M-11.6% | ||
| $2.73M+27.7% | $1.54M-34.2% | $1.74M-30.9% | $1.95M-28.0% | $2.14M-25.6% | ||
| $532.96M+12.8% | $509.1M+8.6% | $480.37M+3.3% | $476.74M+3.2% | $472.39M+3.0% | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Design Therapeutics, Inc.'s total assets?
- Design Therapeutics, Inc. (DSGN) holds $230.4M in total assets, down 3.0% year over year.
- How much debt does Design Therapeutics, Inc. have?
- Design Therapeutics, Inc. carries $2.7M in total debt against $218.1M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Design Therapeutics, Inc. have?
- Design Therapeutics, Inc. holds $12.8M in cash and equivalents.
- Can Design Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 22.28 — current assets exceed current liabilities.
- Where does Design Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.